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Personalised treatments for depression are very much
needed, because all psychological and pharmacological
treatments seem to be equally effective in the aggregate
even thoughwe know that treatment effectiveness varies
substantially at the level of the individual patient.We are
presently, unable to predict which patients will benefit
from which treatments, making it necessary to use a
trial and error approach to the treatment that is almost
certainly implicated in the high rates of treatment drop-
out found among patients in treatment for depression
and delays recovery for those patients who persist with
treatment until a helpful modality is found for them.
Personalised treatments hold out the promise of solving
this problem by predicting which patients will benefit
the most from which treatments. Accurate prediction of
this sort would bring us a step closer to more effective
treatments, which is very much needed because treat-
ments are effective but by far not effective enough.
Unfortunately, despite the attempts from several
research areas, not much success has been made in the
development of personalised treatment and until now
very little personalised advice has been incorporated in
treatment guidelines. Kessler and colleagues suggest
thatwemayhave finally comea step closer todeveloping
true personalised treatments that can be used in clinical
practice (Kessler et al. 2016). Will we finally be able to
take this important step in developing better treatment
for depressive disorders?
The need for personalised treatment of depression
There is no doubt that personalised therapies are very
much needed in the treatment of adult depression.
Several types of antidepressant medication have
been found to be effective compared with placebo,
and several hundreds of trials directly comparing differ-
ent types of medication have shown that all these medi-
cations are most likely about equally effective.
Furthermore, several types of psychotherapy have also
been shown to be effective, such as cognitive behaviour
therapy and interpersonal psychotherapy. Trials directly
comparing different types of psychotherapy have also
shown that there are nooronly small differences between
the effects of these therapies compared with control
groups, and several dozens of studies have shown that
psychotherapies and antidepressant medication are also
about equally effective. So all available treatments, psy-
chological and pharmacological seem to be equally or
about equally effective, while hardly anything is known
about who benefits from which treatment (Cuijpers,
2014), and a trial and error approach is the only approach
that remains.
At the same time the effects of these treatments are
not impressive, as they cannot reduce more than 33%
of the disease burden of depression and that only in
optimal conditions (Andrews et al. 2004). Furthermore,
40% of patients do not or only partially respond to treat-
ment, less than one-third are completely recovered after
treatment, and relapse rates are considerable.
Earlier approaches
Several research disciplines have attempted to
develop personalised treatments of depression.
Pharmacogenetics, where expectations were high, was
thought to improve pharmacotherapies by knowledge of
genotyping (Holsboer, 2008) as about 50% of the response
to antidepressants can be attributed to genetic factors.
Unfortunately, the regulation of gene transcription and
the interactions of these with environmental factors have
been found to be extremely complicated. Therefore, it is
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also very complicated to translate that individual genetic
information into personalised treatments for depression.
Another attempt to develop personalised approaches
to the treatment of depression has been to identify sub-
types of depression that may respond differentially to
different treatments, such as melancholic, atypical, anx-
ious and psychotic depression, early and late-onset
depression, and chronic depression (Baumeister &
Gordon, 2012). Unfortunately, there is no evidence
that these subtypes are either absolutely distinct from
one other or stable (van Loo et al. 2012), and there is
substantial overlap across symptoms, aetiologies and
time of onset. Furthermore, as of now there is very little
evidence that specific subtypes respond better to one
treatment above the other (Baumeister & Gordon,
2012), so also this road to personalised treatment of
depression has not succeeded.
A third approach is based on the concept of clinical
staging. In clinical staging models, a treatment is spe-
cified for each stage. For depression, the stages include:
subthreshold depression, a first episode, a new episode
after having had several earlier ones and chronic
depression. Although this approach is clinically appeal-
ing, there is at this moment insufficient evidence that
clinical staging results in better outcomes.
Comparative trials and moderators
Another approach to personalised treatments comes
from the field of randomised trials. Trials in which
two types of treatment are directly compared with
each other in a specific target population can also iden-
tify patients that benefit more from one treatment than
the other. A considerable number of such comparative
outcome trials in specific patient samples have been
conducted. In a meta-analysis of trials among the spe-
cific target groups comparing antidepressant medica-
tion, psychotherapy and combined treatment we
found that medication is probably the best treatment
for dysthymia and combined treatments are more
effective in depressed older adults (Cuijpers et al.
2012). However, the number of trials that is needed
for this approach is huge. In our meta-analysis, we
found that in order to examine the comparative effect-
iveness of psychotherapy, pharmacotherapy or com-
bined treatment among 20 specific target groups we
required 254 trials for sufficient statistical power,
whereas only 20% of these studies presently have
been conducted.
The last approach to develop personalised therap-
ies has focused on research on outcome moderators.
When two treatments are compared with each other
in an unselected group of participants such modera-
tors of outcome can be examined. Is one of the two
treatments more effective than the other in men or
women, older or younger patients, patients with
comorbid anxiety disorders? The problem with this
approach is that most of these trials are designed
to find (differential) effects of the intervention, not
to find moderators. Therefore, the power is typically
insufficient to identify moderators and significant
findings have a considerable risk of being chance
findings. Furthermore, moderators identified in
such trials can only be considered as indirect evi-
dence. If for example, it would be found that one
treatment is better in women and another in men,
this finding would still be confirmed in a new ran-
domised trial in which women are randomised to
these treatments. So this approach is also not very
promising for the development of personalised
treatments.
Will personalised treatment be possible after all?
The paper by Kessler and colleagues (Kraemer, 2013;
DeRubeis et al. 2014) describes a whole new approach
to personalised treatments. The approaches described
by Kraemer already showed that it is possible to per-
sonalise treatments based on clinical observations
and patient reports obtained prior to beginning treat-
ment. The approach proposed by Kessler has the
promise to further improve and enhance these earlier
approaches. We are not there yet, because none of
these approaches has been tested in a new randomised
trial, showing that patients who receive the persona-
lised treatment do indeed have a bigger chance for a
positive outcome than patients who receive the stand-
ard care. Moreover, the nature of the predictors may
be less than optimal given that these characteristics
may have been measured only once, at the baseline.
Other variables that predict changes in personal
characteristics might themselves be needed. In short,
the approach may be limited by the quality and sensi-
tivity of the personal characteristics. Nevertheless,
after other attempts that did not progress this field,
it is encouraging to see one potential route that
holds alive the promise of personalised treatments
for psychiatry; and this is a good news for patients
with depression.
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